Allergan, Inc. (NYSE:AGN)‘s stock had its “buy” rating restated by research analysts at Leerink Swann in a research note issued on Thursday. Other research analysts have also recently issued reports about the stock. Deutsche Bank decreased their price objective on shares of Allergan from $339.00 to $282.00 and set a “buy” rating for the company […]
